https://doi.org/10.1192/S0007125000144770 Published online by Cambridge University Press

NOW ONCE-DAILY

Give someone with epilepsy a future to look forward to

People with epilepsy have the same aspirations as anybody else. What they need is a treatment which allows them to fulfil their potential.

Whatever the type of epilepsy, Epilim Chrono can help. Effective both in generalized and partial seizures,[1] it is well tolerated (particularly with regard to cognitive function)[2], and offers patients the convenience of once-daily dosing.

It helps people with epilepsy get on with their lives today, and look forward to tomorrow.

Epilim CHRONO Controlled Release

Sodium Valproate Ph. Eur.
Valproic Acid Fr.P

Once-daily management for all forms of epilepsy

https://doi.org/10.1192/S0007125000144770 Published online by Cambridge University Press

REASON TO BE CHEERFUL

LUSTRAL™ 50mg

sertraline

Established in treating depression

Pfizer

CNS DISCOVERY

Abbreviated Prescribing Information: LUSTRAL™ (sertraline) Presentation: Tablets containing 50mg or 100mg sertraline. **Indications:** Treatment of symptoms of depressive illness and accompanying symptoms of anxiety. Prevention of relapse or recurrence of depressive episodes including accompanying symptoms of anxiety. **Dosage:** LUSTRAL should be given as a single daily dose. The initial dose is 50mg and the usual therapeutic dose is 50mg daily. Dosage can be further increased, if appropriate, to 150mg or a maximum of 200mg daily. Patients should be maintained on the lowest effective dose and doses of 150mg or more should not be used for periods exceeding 8 weeks. **Use in children:** Not recommended. **Use in the elderly:** Usual adult dose. **Contra-indications:** Hypersensitivity to LUSTRAL. Hepatic insufficiency. **Use during pregnancy:** LUSTRAL should be used only if clearly needed. **Lactation:** Not recommended. **Precautions, warnings:** Renal insufficiency, unstable epilepsy, ECT, driving. LUSTRAL should be discontinued in a patient who develops seizures. LUSTRAL should not be administered to patients concurrently being treated with tranquillizers who drive or operate machinery. Do not use with, or within two weeks of ending treatment with, MAOIs. At least 14 days should elapse before starting any MAOI following discontinuation of LUSTRAL. Patients should be closely supervised for the possibility of suicide attempt or activation of mania/hypomania. **Drug interactions:** Administer with caution in combination with other centrally active medication. Serotonergic drugs including tryptophan, sumatriptan and fenfluramine should not be used with LUSTRAL. It is recommended that plasma lithium levels be monitored following initiation of LUSTRAL. Although LUSTRAL has been shown to have no adverse interaction with alcohol, concomitant use with alcohol is not recommended. The potential for LUSTRAL to interact with other highly protein bound drugs should be borne in mind. The potential of LUSTRAL to interact with e.g. warfarin, diazepar tolbutamide and cimetidine has not been fully assessed. With warfa prothrombin time should be monitored when LUSTRAL is initiated stopped. **Side-effects:** Dry mouth, nausea, diarrhoea/loose stoo ejaculatory delay, tremor, increased sweating, dyspepsia, dizzines insomnia and somnolence. Asymptomatic elevations in seru transaminases have been reported infrequently (approx. 0.8%) association with LUSTRAL. These usually occurred within the first 9 wee treatment and resolved on cessation of therapy. Malaise and rash have be reported. Seizures (see precautions, warnings). There have been isolat reports of movement disorders and rare cases of hyponatraemia. **Leg category:** POM. **Basic NHS cost:** 50mg tablet (PL 57/0308) Calendar pa of 28, £26.51; 100mg tablet (PL 57/0309) Calendar pack of 28, £39.77. Further information on request.

Invicta™ Pharmaceuticals or
Richborough™ Pharmaceuticals
Divisions of Pfizer Limited, Sandwich, Kent.

RICHBOROUGH PHARMACEUTICALS

https://doi.org/10.1192/S0007125000144770 Published online by Cambridge University Press